, Volume 18, Issue 1, pp 15–18 | Cite as

Das Corticotropin-Releasing-Hormon-System und die Angst

  • Damian Refojo
  • Jan M. DeussingEmail author
Wissenschaft Molekulare Medizin


The corticotropin-releasing hormone (CRH) and its receptors coordinate the body’s stress response. A dysregulation of this system plays a role in the development of psychiatric diseases such as depression and anxiety. The selective deletion of CRH receptor type 1 (CRHR1) in neurons of a specific neurotransmitter identity suggests that an imbalance between CRHR1-controlled anxiogenic glutamatergic and anxiolytic dopaminergic circuits might be causally involved in emotional disorders.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Vale W, Spiess J, Rivier C et al. (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394–1397PubMedCrossRefGoogle Scholar
  2. [2]
    Gallagher JP, Orozco-Cabal LF, Liu J et al. (2008) Synaptic physiology of central CRH system. Eur J Pharmacol 583:215–225PubMedCrossRefGoogle Scholar
  3. [3]
    Holsboer F (1999) The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33:181–214PubMedCrossRefGoogle Scholar
  4. [4]
    Lu A, Steiner MA, Whittle N et al. (2008) Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol Psychiatry 13:1028–1042PubMedCrossRefGoogle Scholar
  5. [5]
    Kimura M, Müller-Preuss P, Lu A et al. (2009) Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol Psychiatry 15:154–165PubMedCrossRefGoogle Scholar
  6. [6]
    Refojo D, Schweizer M, Kuehne C et al. (2011) Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333:1903–1907PubMedCrossRefGoogle Scholar
  7. [7]
    Timpl P, Spanagel R, Sillaber I et al. (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19:162–166PubMedCrossRefGoogle Scholar
  8. [8]
    Müller MB, Zimmermann S, Sillaber I et al. (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6:1100–1107PubMedCrossRefGoogle Scholar
  9. [9]
    Binneman B, Feltner D, Kolluri S et al. (2008) A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165:617–620PubMedCrossRefGoogle Scholar
  10. [10]
    Zobel AW, Nickel T, Künzel HE et al. (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171–181PubMedCrossRefGoogle Scholar
  11. [11]
    Holsboer F, Ising M (2010) Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 61:81–109PubMedCrossRefGoogle Scholar
  12. [12]
    Arzt A, Holsboer F (2006) CRF signaling: molecular specificity for drug targeting in the CNS. Trends Pharmacol Sci 27:531–538PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Max-Planck-Institut Für PsychiatrieMünchenGermany
  2. 2.Molekulare NeurogenetikMax-Planck-Institut für PsychiatrieMünchenGermany

Personalised recommendations